The Scottish Medicines Consortium (SMC) has issued its monthly advice on new medicines.
Rotigotine (Neupro®) has been accepted for the symptomatic treatment of moderate to severe idiopathic restless legs syndrome in adults. Treatment should only be used in patients who score 15 points or more on the International Restless Legs Scale (IRLS).
Calcipotriol and betamethasone gel (Xamiol®) has been accepted for the topical treatment of scalp psoriasis. The combination product has been shown to be more effective than monotherapy in short-term studies.
Action: Clinicians should be aware of the recommendations of the SMC. Routine use of rejected and restricted medicines should be avoided.